StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
FDA Panel Starts Getting Cautious on Sarepta's (SRPT) Eteplirsen
April 25, 2016 12:19 PM
Sarepta Therapeutics (NASDAQ: SRPT) could see some wild trading once it's FDA panel for DMD drug eteplirsen is completed ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Trader Talk
Next Articles
Sarepta Therapeutics (SRPT) Issues Commentary on Adverse FDA Panel Vote for Eeplirsen in DMD
April 26, 2016 5:58 AM
FDA Panel 6 YES, 7 NO That Eteplirsen Shows Clinical Benefit (SRPT)
April 25, 2016 6:12 PM
Sarepta Therapeutics (SRPT) Halted Ahead of FDA AdCom
April 25, 2016 7:02 AM
Sarepta Therapeutics (SRPT) Active Ahead of Today's FDA AdCom and Expected Halt
April 25, 2016 6:40 AM
